- Learn how EpiCept is using its R&D resources and capabilities to discover and develop novel chemical compounds that induce apoptosis
-
View Discovery Engine
Overview
EpiCept is pursuing promising opportunities to develop novel forms of treatment targeting cancer.
Its oncology program contains a cytokine immuno modulator (Ceplene®) which has just received marketing authorization from the European Commission and is a registration stage oncology product in the U.S., Phase I/II stage development candidates, as well as early-stage R&D capabilities focused on novel approaches to induce apoptosis that have the potential to be applied to various cancer treatments.
Programs
Apoptosis Inducers – Lead Anti-Cancer Candidates
Development Pipeline
